IL13RA2 and glioblastoma: For instance, Brown et al. demonstrated the safety and high bioactivity of local anti-IL13Ra2 CAR-T cell administration into the resection cavity of three patients with glioblastoma or intralesional delivery into multifocal glioblastoma.